Further clarity is anticipated from the prospective phase 2 CONFIDENCE study.33 In this ongoing study, approximately 807 patients with CKD associated with T2D (eGFR of 30-90 mL/min/1.73 m2) were randomized to receive monotherapy with finerenone, monotherapy with the SGLT2 inhibitor empagliflozin, or combination therapy with finerenone and empagliflozin. The gene discussed is SLC5A2; the disease is chronic kidney disease.